Search
Confirm
Cancel
ProfoundBio ProfoundBio

APPROACH

Tumors can run, but they can’t hide – we develop targeted therapeutics that seek out and eradicate tumors

imgboxbg

Antibody-drug 
conjugates

imgboxbg

T cell

engagers

PROFOUNDBIO

Mission

Aiming to help patients with cancer through the discovery and development of novel targeted therapeutics with curative potential.

 

We are focused on discovering and advancing novel classes of therapeutics that are designed to leverage the immune system to eradicate cancer.  For patients whose immune systems are insufficient to mount an anti-cancer response, we also develop therapeutics that delivery a small molecule payload specifically to tumor cells.

 

Our team of experienced scientists take a fresh look at how to best eradicate cancer by taking an open, creativity approach to drug discovery and then leverage our broad experience in drug development to take an efficient path to patients.

  • tl

    $138 MM

    +

    Investment

  • tl

    9

    +

    Active Pipeline Programs

  • tl

    40

    YR+

    Combined experience in ADC drug development
    Founding team

ProfoundBio NEWS

Follow us for the latest company updates

ProfoundBio Receives FDA "Study May Proceed" Letter for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload, and Welcomes Naomi Hunder, M.D., as Chief Medical Officer
ProfoundBio Receives FDA "Study May Proceed" Letter for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload, and Welcomes Naomi Hunder, M.D., as Chief Medical Officer
SUZHOU, China and WOODINVILLE, Wash., Aug. 3, 2022 /PRNewswire/ -- ProfoundBio, an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics
See more information
SUZHOU, China and WOODINVILLE, Wash., Aug. 3, 2022 /PRNewswire/ -- ProfoundBio, an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics
ProfoundBio Announces Completion of $70 Million Series A+ Financing to Advance Antibody-Drug Conjugate (ADC) Programs into the Clinic
ProfoundBio Announces Completion of $70 Million Series A+ Financing to Advance Antibody-Drug Conjugate (ADC) Programs into the Clinic
WOODINVILLE, Wash. and SUZHOU, China, June 2, 2022 /PRNewswire/ -- ProfoundBio, a biotech company focusing on the development of novel targeted therapies, announced the closing of a $70 million Series A+ financing round led by Sequoia China.
See more information
WOODINVILLE, Wash. and SUZHOU, China, June 2, 2022 /PRNewswire/ -- ProfoundBio, a biotech company focusing on the development of novel targeted therapies, announced the closing of a $70 million Series A+ financing round led by Sequoia China.
ProfoundBio to Highlight Programs and Technology at AACR 2022 Annual Meeting; Welcomes Zhu Chen, PhD, as Chief Scientific Officer
ProfoundBio to Highlight Programs and Technology at AACR 2022 Annual Meeting; Welcomes Zhu Chen, PhD, as Chief Scientific Officer
Previous page
1
2

ProfoundBio NEWS

Follow us for the latest company updates

Contact us

Address:Suite 101&102, Bldg 1, P3A, 1 Xinze Street, SIP, Suzhou, China
E-mail:info@profoundbio.com

Copyright © 2021 ProfoundBio (Suzhou) Co., Ltd.   All rights reserved. 苏ICP备2021002620号 Powered by www.300.cn